Medcaw Investments Plc - Audited Financial Results for the Year Ended 31 December 2024
(“Medcaw” or the “Company”)
Audited Financial Results for the Year Ended
Medcaw is pleased to announce the publication of the audited results for the year ended
Chairman’s Statement
It is my pleasure to submit the Chairman’s Statement for the Company covering the twelve-month period to
We announced on
The Company understands that AML continues to seek a resolution to the dispute with the
The Company’s shares re-commenced trading on the
I would like to thank our shareholders, my fellow directors and our colleagues at Orana Corporate for their continuing patience and ongoing support.
Non-Executive Chairman
CONTACT:
For more information please visit: https://medcaw-invest.com/
Statement of Comprehensive Income
for the Year Ended
Year ended Year ended
31 December 2024 31 December 2023
Note £ £
Revenue - -
Administrative expenses 4 (267,097) (562,260)
Impairment 11 (196,141) (157,759)
Operating result (463,238) (720,019)
Finance income/(expense) 11 30,878 7,849
Loss before taxation (432,360) (712,170)
Income tax - -
Loss for the year and total comprehensive (432,360) (712,170)
loss for the year
Basic and diluted loss per Ordinary Share 8 (1.95) (3.64)
(pence )
The statement of comprehensive income has been prepared on the basis that all operations are continuing operations.
Statement of Financial Position
As at
As at 31 As at 31
December 2024 December 2023
Note £ £
ASSETS
Current assets
Cash and cash equivalents 9 72,286 371,484
Other current assets 10 26,191 140,323
Loan notes 11 - -
Total assets 98,477 511,807
Liabilities
Current liabilities
Trade & other payables 12 261,781 242,751
Total liabilities 261,781 242,751
Net (Liabilities) / Assets (163,304) 269,056
EQUITY AND LIABILITIES
Equity attributable to owners
Ordinary share capital 13 221,320 221,320
Share premium 13 1,005,110 1,005,110
Share based payment reserve 14 14,903 14,903
Accumulated losses (1,404,637) (972,277)
Total equity and liabilities (163,304) 269,056
Statement of Changes in Equity
For the Year Ended
Ordinary share Share based Retained
capital Share premium payment earnings Total equity
reserve
£ £ £ £ £
As at 31 171,320 679,110 - (260,107) 590,323
December 2022
Comprehensive
loss for the
year
Loss for the - - - (712,170) (712,170)
year
Total
comprehensive - - - (712,170) (712,170)
loss for the
year
Transactions
with owners
Warrants
issued during - - 14,903 - 14,903
year
Ordinary
shares issued 50,000 350,000 - - 400,000
during year
Share issue - (24,000) - - (24,000)
costs
Total
transactions 50,000 326,000 14,903 - 390,903
with owners
As at 31 221,320 1,005,110 14,903 (972,277) 269,056
December 2023
Comprehensive
loss for the
year
Loss for the - - - (432,360) (432,360)
year
Total
comprehensive - - - (432,360) (432,360)
loss for the
year
Transactions - - - - -
with owners
Warrants
issued during - - - - -
year
Ordinary
shares issued - - - - -
during year
Share issue - - - - -
costs
Total
transactions - - - - -
with owners
As at 31 221,320 1,005,110 14,903 (1,404,637) (163,304)
December 2024
Consolidated Statement of Cashflows
Notes Year ended 31 December Year ended 31 December
2024 2023
£ £
Cash flows from operating
activities
Loss before income tax (432,360) (712,170)
Adjustments for:
Impairment 11 196,141 157,759
Share based payments 14 - 14,903
Adjustments for changes in
working capital:
Decrease in trade and 114,132 (140,323)
other receivables
Decrease in trade and 19,030 1,241
other payables
Interest income (30,878) (7,849)
Net cash used in operating (133,935) (686,439)
activities
Cash flows from financing
activities
Cash received from issue - 563,160
of Ordinary Shares
Net cash from financing - 563,160
activities
Cash flows from investing
activities
Loan notes 11 (165,263) (149,109)
Net cash used in investing (165,263) (149,109)
activities
Net decrease in cash and (299,198) (272,388)
cash equivalents
Cash and cash equivalents 371,484 643,872
at beginning of year
Cash and cash equivalents 72,286 371,484
at end of year
Notes to the Financial Statements
For the Year Ended
1. General Information
The Company was incorporated on
The address of its registered office is Eccleston Yards, 25 Eccleston Place London SW1W 9NF
The principal activity of the Company is to pursue one or more acquisitions.
The Company listed on the
1. Accounting policies
The principal accounting policies applied in preparation of these financial statements are set out below. These policies have been consistently applied unless otherwise stated.
2.1 Basis of preparation
The principal accounting policies applied in the preparation of the Financial Statements are set out below. These policies have been consistently applied to the year presented, unless otherwise stated.
The Company Financial Statements have been prepared in accordance with
The Company Financial Statements are presented in £ unless otherwise stated.
2.2 Going concern
The Company’s business activities, together with facts likely to affect its future operations and financial and liquidity positions are set out in the Chairman’s Statement and the Strategic Report.
The Company’s financial statements have been prepared on the going concern basis, which contemplates that the Company will be able to realize its assets and discharge liabilities in the normal course of business. Despite this, there can be no assurance that the Company will either achieve or maintain profitability in the future and financial returns arising therefrom, may be adversely affected by factors outside the control of the Company.
The Company has had recurring losses in the current year and prior period, and its continuation as a going concern is dependent on the Company’s ability to successfully fund its operations by obtaining additional financing from equity injections or other funding.
This indicates that a material uncertainty exists that may cast significant doubt over the Company’s ability to continue as a going concern.
Whilst acknowledging this material uncertainty, the directors consider it appropriate to prepare the financial statements on a going concern basis for the following reasons:
-- The Company may reasonably expect to maintain continued support from
shareholders and other financiers that have supported the Company’s
previous capital raising to assist with meeting future funding needs;
and
-- All outgoing and expenditure can be suspended until the sufficient
completion of a capital raise.
The financial statements do not include the adjustments that would result if the Company were unable to continue as a going concern. The auditors have made reference to going concern by way of a material uncertainty within their report.
2.3 Cash and cash equivalents
Cash and cash equivalents comprise cash at bank and in hand, and demand deposits with banks and other financial institutions.
2.4 Equity
Share capital is determined using the nominal value of shares that have been issued.
The Share premium account includes any premiums received on the initial issuing of the share capital. Any transaction costs associated with the issuing of shares are deducted from the Share premium account, net of any related income tax benefits.
Equity-settled share-based payments are credited to a share-based payment reserve as a component of equity until related options or warrants are exercised or lapse.
Retained losses includes all current and prior year results as disclosed in the income statement.
2.5 Foreign currency translation
The financial statements are presented in Sterling which is the Company’s functional and presentational currency.
Transactions in currencies other than the functional currency are recognised at the rates of exchange on the dates of the transactions. At each reporting date, monetary assets and liabilities are retranslated at the rates prevailing at the balance sheet date with differences recognised in the Statement of comprehensive income in the year in which they arise.
2.6 Financial instruments
IFRS 9 requires an entity to address the classification, measurement and recognition of financial assets and liabilities.
a) Classification
The Company classifies its financial assets in the following measurement categories:
-- those to be measured subsequently at fair value (either through OCI or
through profit or loss);
-- those to be measured at amortised cost; and
-- those to be measured subsequently at fair value through profit or loss.
The classification depends on the Company’s business model for managing the financial assets and the contractual terms of the cash flows.
For assets measured at fair value, gains and losses will be recorded either in profit or loss or in OCI. For investments in equity instruments that are not held for trading, this will depend on whether the Company has made an irrevocable election at the time of initial recognition to account for the equity investment at fair value through other comprehensive income (FVOCI).
b) Recognition
Purchases and sales of financial assets are recognised on trade date (that is, the date on which the Company commits to purchase or sell the asset). Financial assets are derecognised when the rights to receive cash flows from the financial assets have expired or have been transferred and the Company has transferred substantially all the risks and rewards of ownership.
c) Measurement
At initial recognition, the Company measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss (FVPL), transaction costs that are directly attributable to the acquisition of the financial asset.
Transaction costs of financial assets carried at FVPL are expensed in profit or loss.
Debt instruments
Amortised cost: Assets that are held for collection of contractual cash flows, where those cash flows represent solely payments of principal and interest, are measured at amortised cost. Interest income from these financial assets is included in finance income using the effective interest rate method. Any gain or loss arising on derecognition is recognised directly in profit or loss and presented in other gains/(losses) together with foreign exchange gains and losses. Impairment losses are presented as a separate line item in the statement of profit or loss.
d) Impairment
The Company assesses, on a forward-looking basis, the expected credit losses associated with any debt instruments carried at amortised cost. The impairment methodology applied depends on whether there has been a significant increase in credit risk. For trade receivables, the Company applies the simplified approach permitted by IFRS 9, which requires expected lifetime losses to be recognised from initial recognition of the receivables.
2.7 Equity instruments
Equity instruments issued by the Company are recorded at the proceeds received net of any direct issue costs.
2.8 Share based payments
The Group issues equity-settled share based payments to certain advisors.
Equity-settled Share based payments are measured at fair value at the date of grant.
Fair value is measured using an appropriate options pricing model. The expected life used in the model has been adjusted, based on management’s best estimate, for the effects of non-transferability, exercise restrictions and behavioural considerations.
The fair value determined at the grant date of the equity-settled Share based payments is expensed on a straight-line basis over the vesting period, together with a corresponding increase in equity, based upon the Group’s estimate of the shares that will eventually vest.
Where the terms of an equity-settled transaction are modified, as a minimum an expense is recognised as if the terms had not been modified. In addition, an expense is recognised for any increase in value of the transaction as a result of the modification, as measured at the date of the modification.
Where an equity-settled transaction is cancelled, it is treated as if it had vested on the date of cancellation, and any expense not yet recognised for the transaction is recognised immediately. However, if a new transaction is substituted for the cancelled transaction and designated as a replacement transaction on the date that it is granted, the cancelled and new transactions are treated as if they were a modification of the original transaction, as described in the previous paragraph.
2.9 Taxation
Tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the income statement because it excludes items of income and expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.
2.10 Critical accounting judgements and key sources of estimation uncertainty
The preparation of the financial statements in conformity with IFRSs requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expense. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the year in which the estimates are revised and in any future years affected.
Estimation of fair value of warrants issued in the year
The fair value of the warrants issued during the period have been calculated using a Black Scholes model which requires a number of assumptions and inputs, see Note 14 below.
2.11 New standards and interpretations not yet adopted
At the date of approval of these financial statements, the following standards and interpretations which have not been applied in these financial statements were in issue but not yet effective (and in some cases have not yet been adopted by the
______________________________________________________________________________ |Standard |Effective date |Overview | |___________________________|_____________________|____________________________| | | |The standard has been | | | |amended to clarify that the | | | |classification of | | | |liabilities as current or | | | |non-current should be based | | | |on rights that exist at the | | | |end of the reporting period.| | | | | | | |In order to conclude a | | | |liability is non-current, | |Amendments to IAS 1 | |the right to defer | | | |settlement of a liability | |Classification of |1 January 2024 (early|for at least 12 months after| |Liabilities as Current or |adoption permitted) |the reporting date must | |Non-current | |exist as at the end of the | | | |reporting period. | | | | | | | |The amendments also clarify | | | |that (for the purposes of | | | |classification as current or| | | |non-current), settlement is | | | |the transfer of cash, the | | | |entity’s own equity | | | |instruments (except as | | | |described below), other | | | |assets or services. | |___________________________|_____________________|____________________________| | | |The amendments have been | | | |made to clarify: | | | | | | | |- when a currency is | |Amendments to IAS 21 – Lack|1 January 2025 (early|exchangeable into another | |of Exchangeability |adoption permitted) |currency; and | | | | | | | |- how a company estimates a | | | |spot rate when a currency | | | |lacks exchangeability. | |___________________________|_____________________|____________________________|
1. Segmental analysis
The Company manages its operations in one segment, being seeking a suitable investment. The results of this segment are regularly reviewed by the board as a basis for the allocation of resources, in conjunction with individual investment appraisals, and to assess its performance.
1. Operating Loss
Operating loss for the company is stated after charging:
Year ended Year ended
31 December 2024 31 December 2023
£ £
Directors’ fees 72,000 108,000
Professional Fees (Legal & accounting) 105,217 364,949
Listing expenses 47,468 65,983
Other administrative expenses 15,532 28,184
Insurance 26,880 27,418
VAT provision written back - (32,274)
267,097 562,260
1. Directors’ and Employees
The average number of persons employed by the Company (including executive and non-executive directors) during the year ended
Year ended Year ended
No of employees
31 December 2024 31 December 2023
Management 3 3
3 3
The aggregate payroll costs of these persons were as follows:
£ £
Wages and salaries 72,000 108,000
72,000 108,000
Year ended Year ended
31 December 2024 31 December 2023
£ £
Fees to directors 72,000 108,000
72,000 108,000
1. Auditor’s Remuneration
Year ending Year ending
31 December 2024 31 December 2023
£ £
Fees payable to the Company’s auditor for the 30,000 35,000
audit of the Company
30,000 35,000
1. Taxation
As at As at
31 December 2024 31 December 2023
£ £
A reconciliation of the tax charge / credit
appearing in the income statement to the tax
that would result from applying the standard
rate of tax to the results for the year is:
Loss per accounts (432,360) (712,170)
Tax credit at the standard rate of corporation (82,148) (135,312)
tax in the UK of 19%
Adjustment for items disallowable for tax - -
Tax losses for which no deferred tax is 82,148 135,312
recognised
Tax expense recognised in accounts - -
The Company has total carried forward losses of £1,247,778 (2023: £ 815,418). The taxed value of the unrecognised deferred tax asset is £238,397 (2023: £156,249 ) and these losses do not expire. No deferred tax assets in respect of tax losses have been recognised in the accounts because there is currently insufficient evidence of the timing of suitable future taxable profits against which they can be recovered.
1. Earnings per share
The calculation of the basic and diluted earnings per share is calculated by dividing the profit or loss for the year by the weighted average number of ordinary shares in issue during the year.
31 December 2024 31 December 2023
£ £
Loss attributable to shareholders of Medcaw (432,360) (712,170)
Investments Plc
Weighted number of ordinary shares in issue 22,132,095 19,563,414
Basic & dilutive earnings per share from (1.95) (3.64)
continuing operations - pence
There is no difference between the diluted loss per share and the basic loss per share presented. Share options and warrants could potentially dilute basic earnings per share in the future but were not included in the calculation of diluted earnings per share as they are anti-dilutive for the year presented. See note 13 for further details.
1. Cash and cash equivalents
As at As at
31 December 2024 31 December 2023
£ £
Cash at bank 72,286 371,484
72,286 371,484
1. Other current assets
As at As at
31 December 2024 31 December 2023
£ £
IPO Funds - 36,100
Prepayments 24,746 104,223
VAT 1,445 -
26,191 140,323
1. Loan note
As at As at
31 December 2024 31 December 2023
£ £
Loan note 315,173 149,109
Interest receivable 38,727 7,849
Provision for doubtful debts (353,900) (157,759)
- -
On 23
rd
1. Trade and other payables
As at As at
31 December 2024 31 December 2023
£ £
Trade payables 16,327 97,297
Accruals 245,454 145,454
261,781 242,751
1. Share capital and share premium
Share Capital Share Premium Total
Ordinary Shares
£ £ £
At 31 December 2022 17,132,095 171,320 679,110 850,430
Issue of ordinary shares 5,000,000 50,000 350,000 400,000
Share issue costs - - (24,000) (24,000)
At 31 December 2023 22,132,095 221,320 1,005,110 1,226,430
Issue of ordinary shares - - - -
Share issue costs - - - -
At 31 December 2024 22,132,095 221,320 1,005,110 1,226,430
1
On 6
th
The share premium represents the difference between the nominal value of the shares issued and the actual amount subscribed less; the cost of issue of the shares, the value of the bonus share issue, or any bonus warrant issue.
The Company has only one class of share. All ordinary shares have equal voting rights and rank pari passu for the distribution of dividends and repayment of capital.
1. Share based payments reserve
2024 2023
£ £
Opening balance 14,903 -
Broker warrants - 41
Advisor warrants - 14,862
Adviser warrants - -
At 31 December 14,903 14,903
The fair value of the services received in return for the warrants granted are measured by reference to the fair value of the warrants granted. The estimate of the fair value of the warrants granted is measured based on the Black-Scholes valuations model. Measurement inputs and assumptions are as follows:
Broker Advisor Adviser
Issue date 06/07/2023 06/07/2023 01/9/2023
Time to expiry 2 2 3
Share price at date of issue of warrants 5p 5p 5p
Exercise price 8p 4p 32p
Expected volatility 18.4% 18.4% 18.4%
Risk free interest rate 4.3% 4.3% 4.3%
Warrants
As at 31 December 2024
Number of
Weighted average exercise price
warrants
Brought forward at 1 January 2024 20p 13,712,500
Expired during the year 4p (4,000,000)
Expired during the year
Cancelled 32p (7,812,500)
Granted in year - -
Vested in year - -
Outstanding at 31 December 2024 5.3p 1,900,000
Exercisable at 31 December 2024 5.3p 1,900,000
The weighted average time to expiry of the warrants as at
1. Financial Instruments and Risk Management
Principal financial instruments
The principal financial instruments used by the Company from which the financial risk arises are as follows:
31 December 2024 31 December 2023
£ £
Financial Assets at amortised cost
Cash and cash equivalents 72,286 371,484
Loan note - -
72,286 371,484
Financial Liabilities at amortised cost
Trade and other payables 16,327 97,297
16,327 97,297
The financial liabilities are payable within one year.
General objectives and policies
Per the Directors report the overall objective of the Board is to set policies that seek to reduce risk as far as practical without unduly affecting the Company’s competitiveness and flexibility. Further details regarding these policies are:
Policy on financial risk management
The Company’s principal financial instruments comprise cash and cash equivalents, loan receivables, trade and other payables. The Company’s accounting policies and methods adopted, including the criteria for recognition, the basis on which income and expenses are recognised in respect of each class of financial asset, financial liability and equity instrument are set out in note 2 – “Accounting Policies”.
The Company does not use financial instruments for speculative purposes. The carrying value of all financial assets and liabilities approximates to their fair value.
Derivatives, financial instruments and risk management
The Company does not use derivative instruments or other financial instruments to manage its exposure to fluctuations in foreign currency exchange rates, interest rates and commodity prices.
Credit risk
Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in financial loss to the Company. The Company has adopted a policy of only dealing with creditworthy counterparties. The Company’s exposure and the credit ratings of its counterparties are monitored by the Board of Directors to ensure that the aggregate value of transactions is spread amongst approved counterparties.
The Company applies IFRS 9 to measure expected credit losses for its loan receivables, these are regularly monitored and assessed. Loans are subject to an expected credit loss provision when it is probable that amounts outstanding are not recoverable as set out in the accounting policy. Due to the inherent uncertainty in the recoverability of the loan to AML the Company has raised a provision against the full amount and an impairment charge has been recorded.
The Company’s principal financial assets are cash and cash equivalents and a loan note. Cash equivalents include amounts held on deposit with financial institutions. The loan note is an unsecured loan accruing interest at 10% per annum. The loan is repayable upon demand by the lender and can be converted into shares in AML subject to certain milestones not being met. As at reporting date the loan has not been converted to equity
The credit risk on liquid funds held in current accounts and available on demand is limited because the Company’s counterparties are banks with high credit-ratings assigned by international credit-rating agencies.
No financial assets have indicators of impairment.
The Company’s maximum exposure to credit risk is limited to the carrying amount of financial assets recorded in the financial statements.
Liquidity risk
During the
In managing liquidity risk, the main objective of the Company is to ensure that it has the ability to pay all of its liabilities as they fall due. The Company monitors its levels of working capital to ensure that it can meet its liabilities as they fall due.
The table below shows the undiscounted cash flows on the Company’s financial liabilities as at
Total Within 2 months Within 2-6 months
£ £ £
At 31 December 2024
Trade payables 16,327 16,327 -
Accruals 245,454 245,454 -
Total Within 2 months Within 2-6 months
£ £ £
At 31 December 2023
Trade payables 97,297 97,297 -
Accruals 145,454 145,454 -
Capital management
The Company considers its capital to be equal to the sum of its total equity. The Company’s objective when managing its capital is to ensure it obtains sufficient funding for continuing as a going concern. The Company funds its capital requirements through the issue of new shares to investors.
1. Related Party Transactions
Provision of services
During the year £22,673 (2023: £107,225) was incurred for the provision of administrative and corporate accounting services from
1.Ultimate Controlling Party
As at
1. Capital Commitments
As at
1. Subsequent events
On
